Clinical and transcriptional response to the long‐acting interleukin‐1 blocker canakinumab in Blau syndrome–related uveitis
To report on the clinical response to canakinumab in a patient with sporadic nucleotide-binding oligomerization domain-containing protein 2 (NOD-2)-associated pediatric granulomatous arthritis (Blau syndrome) and severe resistant panuveitis, and to describe gene expression profile changes throughout...
Sábháilte in:
Príomhchruthaitheoirí: | , , , , , , |
---|---|
Formáid: | Artigo |
Teanga: | Béarla |
Foilsithe / Cruthaithe: |
2012
|
Rochtain ar líne: | https://doi.org/10.1002/art.37776 |
Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|